Search the Newsreel

Does Compass Minerals International (CMP) New COO Appointment Signal An Operational Shift?

Compass Minerals International (NYSE:CMP) has appointed Brandon Risner as its new Chief Operating Officer, effective August 3, 2026, succeeding Patrick Merrin. Risner's extensive experience in the mining industry and prior tenure with the company suggest a continuity of existing operational strategies rather than a …

Rhythm Pharmaceuticals (RYTM) Stock Looks Pricey Following Strong IMCIVREE News

Zentalis raises $92.6M for trials, filings and what follows

Zentalis Pharmaceuticals has closed an underwritten public offering, raising approximately $92.6 million in gross proceeds from the sale of 26,450,000 common shares at $3.50 each. The proceeds, including those from the underwriters' fully exercised option, will be used to fund clinical trials, preclinical studies, …

What will Amylyx's Phase 3 trial show when results arrive Aug. 18?

Why Applied Materials (AMAT) Could Be a Major Winner of the AI Memory Surge

Aristotle Capital Management, LLC, an investment management company, released its "Core Equity Fund" Q2 2026 investor letter. A copy of the letter can be downloaded here. The fund returned 14.69% in the second quarter of 2026, slightly trailing the 15.20% gain of the S&P …

CSW Industrials (CSW) CEO sells 1,500 shares under 10b5-1 plan

CSW Industrials, Inc.'s Chairman, President & CEO, Joseph B. Armes, sold 1,500 shares of common stock at a weighted average price of $345.1574 per share on August 14, 2026. This transaction was conducted under a Rule 10b5-1 trading plan established on August 12, 2025. …

Piper Sandler Maintains Rigel Pharmaceuticals(RIGL.US) With Hold Rating, Raises Target Price to $49

Piper Sandler has reiterated its Hold rating on Rigel Pharmaceuticals (RIGL.US) and increased its price target to $49. This adjustment reflects the firm's continued evaluation of the company's financial and market position.

Is Earnings Strength And Capital Returns Altering The Investment Case For Triple Flag (TSX:TFPM)?

Triple Flag Precious Metals Corp. recently reported strong second-quarter and first-half 2026 results, with increased sales, reaffirmed full-year guidance, a dividend hike, and a share repurchase program. These actions highlight management's commitment to returning capital to shareholders while growing its royalty and streaming portfolio. …

Is Globalstar (GSAT) Cheap After Earnings And New Satellite Launches?

Martin Leb Juravsky Sells 5,682 Shares of Russel Metals (TSE:RUS) Stock

Applied Materials Earnings Highlight AI Demand, Yet Capacity Constraints Remain the Limit

Applied Materials exceeded revenue and guidance expectations, reflecting strong AI-driven chip demand, but its stock declined due to a lack of specific future systems guidance. The company is prioritizing manufacturing capacity expansion to address physical production limits that are now the primary constraint on …

EyePoint Stock Craters 69% After Drug Trial Failure. It May Be an Overreaction.

EyePoint Pharmaceuticals (EYPT) shares plummeted by 69% after its lead pipeline candidate, Duravyu, missed primary endpoints in two Phase 3 trials for a severe eye disease. Despite management calling the results "clinically meaningful," the market reacted strongly to the trial failure. The article suggests …

Xeris Biopharma Holdings (XERS) Could Be 23% Undervalued As Guidance Tightens And Pipeline Progress Continues

Applied Materials Q3 FY 2026: Advanced Packaging and DRAM Accelerate Growth

Applied Materials (AMAT) reported a record-breaking Q3 FY 2026, driven by strong demand for AI infrastructure in semiconductor manufacturing equipment, DRAM, and advanced packaging. The company exceeded revenue and EPS expectations, with Semiconductor Systems revenue up 27% YoY and Applied Global Services up 22% …

SpaceX Stock Tests Resistance, Attempts To Retake Debut Price

SpaceX stock jumped more than 5% Monday, fighting to recover its 150 debut price. SpaceX conducts rapid Falcon 9 launches. Continue Reading

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Receives "Neutral" Rating from JPMorgan Chase & Co.

Modi Naturals Q1 Results: PAT up 19.1% YoY to ₹12.5 crore

Why Talon Metals Corp stock is rising today

Martin Marietta Materials Inc. stock underperforms Monday when compared to competitors

Shares of Martin Marietta Materials Inc. (MLM) fell 1.69% on Monday, underperforming the broader market. This drop occurred during a negative trading session where the S&P 500 Index and Dow Jones Industrial Average also experienced declines. The stock's fall ended a two-day winning streak.

Vulcan Materials Co. stock outperforms competitors despite losses on the day

Shares of Vulcan Materials Co. (VMC) declined by 1.37% to $278.15, on a day when the broader market also saw losses, with the S&P 500 Index (SPX) falling 0.52% and the Dow Jones Industrial Average (DJIA) falling 0.51%. Despite the daily loss, the article …

Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX

Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Crinetics Pharmaceuticals, Inc. (CRNX) to Vertex Pharmaceuticals Incorporated (VRTX) for $85.00 per share in cash. KSF is scrutinizing whether this acquisition price and the process leading to it adequately value Crinetics Pharmaceuticals, …

At US$507, Is Applied Materials, Inc. (NASDAQ:AMAT) Worth Looking At Closely?

This article analyzes Applied Materials, Inc. (NASDAQ:AMAT) from a valuation perspective, questioning if its current share price of US$507 makes it an attractive investment. It suggests a closer look at the company's financial health and future prospects to determine if it is undervalued or …

Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day

Vertex Pharmaceuticals Inc. (VRTX) saw its stock rise by 1.94% to $515.55 on Monday, despite a negative overall trading session for the stock market, which saw the S&P 500 Index and Dow Jones Industrial Average fall. This increase broke a three-day losing streak for …

Applied Materials Inc. stock outperforms competitors on strong trading day

Shares of Applied Materials Inc. (AMAT) rose 5.55% to $535.31 on Monday, outperforming the broader market which saw declines in the S&P 500 Index and Dow Jones Industrial Average. This increase snapped a two-day losing streak for the stock.

REGN UPCOMING DEADLINE: Levi & Korsinsky Alerts Regeneron

Levi & Korsinsky, LLP is alerting investors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) about a pending securities class action. The lawsuit alleges that Regeneron made misleading statements regarding its Phase III Fianlimab-Libtayo Study, which led to a significant stock price drop. Investors who purchased …

Diversified Marine Delivers Second Towboat To Vulcan Materials

Diversified Marine has delivered the M/V Edwin Rider, its second inland towboat for Vulcan Materials, built at their shipyard in Bourg, Louisiana. The vessel is 72 feet long and features a twin-screw propulsion system with two Mitsubishi S6R2 Tier 3 engines, totaling 1,600 horsepower, …

Why Medexus Pharmaceuticals Inc stock is sliding today

Modi Naturals wins Rs 140 crore ethanol order from OMCs

Why Platinum Group Metals Ltd stock is rising today

Mirum Pharmaceuticals (MIRM) Q2 2026 Earnings Call Transcript

Andean Precious Metals Stock: A Deliberate Bet on Higher Silver Prices

Altius Minerals Stock: Royalty Revenue Doubles to a Record C$30 Million

Altius Minerals (TSX:ALS): Is Valuation Getting Stretched?

Corvus Pharmaceuticals (CRVS): This Clinical-Stage Drugmaker Just Got A Lot More Interesting

On August 6, Corvus Pharmaceuticals (NASDAQ:CRVS) held its second-quarter 2026 earnings call, and the story was almost entirely about one molecule. Soquelitinib, the company's oral ITK inhibitor, is now being tested across five different diseases at once, from a rare blood cancer to asthma. …

2026 Stock-Split Watch: Is United Rentals on Deck?

When a stock reaches a certain price, some will worry that the buying pool becomes more limited, as retail investors may feel priced out. Often, when a stock hits $1,000 per share, that seems to be a psychological price level at which more shareholders …

PHAT Maintains Overweight Rating -- Price Target Lowered to $14

Barclays has maintained an "Overweight" rating for Phathom Pharmaceuticals (PHAT) but lowered its price target from $18.00 to $14.00, reflecting a cautious outlook despite the company being significantly undervalued according to GuruFocus's GF Value™. The company, which specializes in gastrointestinal treatments, faces financial health …